Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
Encouraging objective response rate of 52.4% was seen with ifinatamab deruxtecan in heavily pretreated patients…
Encouraging objective response rate of 52.4% was seen with ifinatamab deruxtecan in heavily pretreated patients…
An objective response rate of 29.8% was observed with patritumab deruxtecan in heavily pretreated patients…
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab with or without chemotherapy demonstrated objective response…
 TAIPEI,Taiwan--(BUSINESS WIRE)--TVBS, the Taiwanese broadcasting network that kicked off operations in 1993, marks its…
SINGAPORE--(BUSINESS WIRE)--#insurance--AM Best has downgraded the Financial Strength Rating to B++ (Good) from A- (Excellent)…
The Australian-born brand beloved by Gen Z makes its U.S. debut SAN FRANCISCO--(BUSINESS WIRE)--a.k.a. Brands…
Financial LLM is in closed test with financial institution partners on Ant Group’s wealth management…
PARIS--(BUSINESS WIRE)--Zhuyeqing Tea is regarded as the gift of China in the New Silk Road…
HONG KONG--(BUSINESS WIRE)--At this year’s INCLUSION · Conference on the Bund, Ant Group Digital Technologies…
Federal Court of Australia Orders Convening of Scheme Meeting and Dispatch of Scheme Booklet DENVER--(BUSINESS…